- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | BullFrog AI: Aktionäre stimmen für Kapitalerhöhung und Aktienzusammenlegung | 2 | Investing.com Deutsch | ||
| BULLFROG AI Aktie jetzt für 0€ handeln | |||||
| Fr | BullFrog AI Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Fr | RedChip Companies, Inc.: BullFrog AI and Bimergen Energy Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 290 | ACCESS Newswire | ORLANDO, FLORIDA / ACCESS Newswire / October 24, 2025 / RedChip Companies will air interviews with BullFrog AI, Inc. (Nasdaq:BFRG) and Bimergen Energy Corp. (OCTQB:BESS) on the RedChip Small Stocks... ► Artikel lesen | |
| 10.10. | Bullfrog AI files to sell 5M shares of common stock for holders | 4 | Seeking Alpha | ||
| 10.10. | BullFrog AI Holdings, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 09.10. | BullFrog AI Holdings, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 23.09. | Bullfrog AI ändert Satzung und wählt Direktoren auf Hauptversammlung | 1 | Investing.com Deutsch | ||
| 23.09. | BullFrog AI Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.09. | BullFrog AI Holdings, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 08.09. | BullFrog AI Holdings, Inc.: BullFrog AI's bfPREP and bfLEAP Platforms Deliver Real-World Impact in Eleison Pharmaceuticals Collaboration | 7 | GlobeNewswire (USA) | ||
| 27.08. | BullFrog AI Holdings, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 13.08. | BullFrog AI Holdings, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 22.07. | BullFrog AI Holdings, Inc.: Rethinking R&D: BullFrog AI White Paper Outlines New Blueprint for Smarter Drug Development | 4 | GlobeNewswire (USA) | ||
| 18.07. | RedChip Companies, Inc.: Processa Pharmaceuticals and BullFrog AI Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 397 | ACCESS Newswire | ORLANDO, FLORIDA / ACCESS Newswire / July 18, 2025 / RedChip Companies will air interviews with Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) and BullFrog AI, Inc. (Nasdaq:BFRG) on the RedChip Small... ► Artikel lesen | |
| 20.06. | BullFrog AI Holdings, Inc.: BullFrog AI's Dr. Juan Felipe Beltrán to Highlight Advanced AI Strategies in Bioinformatics at XTalks Webinar | 3 | GlobeNewswire (USA) | ||
| 12.06. | BullFrog AI Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.06. | BullFrog AI Holdings, Inc.: BullFrog AI Announces Strategic Collaboration with Sygnature Discovery to Introduce BullFrog Data Networks to Global Biopharma Clients | 2 | GlobeNewswire (USA) | ||
| 13.05. | BullFrog AI Holdings, Inc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 11.04. | RedChip Companies, Inc.: Bullfrog AI and Connect Biopharma Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 419 | ACCESS Newswire | ORLANDO, FLORIDA / ACCESS Newswire / April 11, 2025 / RedChip Companies will air interviews with Bullfrog AI Holdings, Inc. (Nasdaq:BFRG) and Connect Biopharma Holdings Limited (Nasdaq:CNTB) and on... ► Artikel lesen | |
| 27.12.24 | BullFrog AI Holdings, Inc.: BullFrog AI Issues Letter to Stockholders | 273 | GlobeNewswire (Europe) | GAITHERSBURG, Md., Dec. 27, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BB BIOTECH | 44,250 | +0,68 % | BB Biotech überzeugt mit starkem Quartal | Die Schweizer Beteiligungsgesellschaft legt einen beeindruckenden Lauf hin. BB Biotech (ISIN CH0038389992) steigerte im dritten Quartal den Nettoinventarwert um 24 Prozent in Franken. Der Aktienkurs... ► Artikel lesen | |
| QIAGEN | 40,980 | -0,39 % | QIAGEN N.V.: QIAGEN Marks 4,000th QIAcube Connect Placement, Reaffirming Leadership in Automated Sample Processing | QIAcube Connect drives lab efficiency by automating critical steps in molecular biology workflows for both research and clinical customers Milestone builds on nearly 13,000 cumulative placements... ► Artikel lesen | |
| AMGEN | 252,25 | +0,74 % | AstraZeneca And Amgen's Tezspire Approved In EU For Severe Nasal Polyps | THOUSAND OAKS (dpa-AFX) - AstraZeneca (AZN) and Amgen (AMGN) announced that Tezspire (tezepelumab) has received European Union approval as an add-on therapy with intranasal corticosteroids for... ► Artikel lesen | |
| NOVAVAX | 7,201 | -1,42 % | Novavax, Inc.: Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy | Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million... ► Artikel lesen | |
| STRYKER | 318,00 | -1,46 % | Dividendenbekanntmachungen (30.09.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACADIA REALTY TRUST US0042391096 0,2 USD 0,1705 EUR ADVANCED FLOWER CAPITAL INC US00109K1051 0,15 USD 0,1279 EUR AG MORTGAGE INVESTMENT... ► Artikel lesen | |
| ILLUMINA | 82,33 | -2,28 % | Biotech-Wende: Nach 4 Jahren Crash: Illumina-Aktie vor massivem Kaufsignal | Die Aktie des Krebsforschungsspezialisten Illumina steckt seit Jahren in einem Abwärtstrend. Doch nun mehren sich die Anzeichen für eine Trendwende. Die Aktie hat die Mehrjahrestiefs hinter sich gelassen... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 54,00 | -2,70 % | CRISPR Therapeutics AG: CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe | ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based... ► Artikel lesen | |
| AAP IMPLANTATE | 1,510 | +2,03 % | EQS-News: aap Implantate AG mit starkem Wachstum in Q3/2025: +15% | EQS-News: aap Implantate AG
/ Schlagwort(e): 9-Monatszahlen
aap Implantate AG mit starkem Wachstum in Q3/2025: +15%
28.10.2025 / 08:00 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| OCUGEN | 1,302 | -1,40 % | Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results | ||
| SANGAMO THERAPEUTICS | 0,519 | +1,41 % | Sangamo Therapeutics: Die Chance ist noch nicht vom Tisch! | ||
| INTELLIA THERAPEUTICS | 11,180 | -6,40 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) | CAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia | Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX, May 04, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| TEMPUS AI | 76,00 | +2,01 % | Tempus AI (TEM) Stock Gets a $110 Price Target on Rising AI Adoption in Medicine | ||
| DEFENCE THERAPEUTICS | 0,495 | 0,00 % | Defence Therapeutics Inc.: Defence to Present New Scientific Data on Its ADC-Enhancing Accum Technology at the World ADC Conference in San Diego, USA, November 4-5, 2025 | Montreal, Quebec--(Newsfile Corp. - October 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug... ► Artikel lesen | |
| EDITAS MEDICINE | 2,710 | +0,41 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen |
BULLFROG AI HOLDINGS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -4,29 % bei einem Aktienkurs von 1,340 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BULLFROG AI HOLDINGS INC finden Sie auf Wallstreet Online.